Comparative Pharmacology
Head-to-head clinical analysis: DRAX EXAMETAZIME versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAX EXAMETAZIME versus SETHOTOPE.
DRAX EXAMETAZIME vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAX EXAMETAZIME is a diagnostic radiopharmaceutical composed of technetium-99m (Tc-99m) labeled to exametazime (hexamethylpropyleneamine oxime, HMPAO). It passively diffuses across the blood-brain barrier and is rapidly converted to a hydrophilic complex, which is trapped in brain tissue. Distribution is proportional to regional cerebral blood flow, allowing SPECT imaging of cerebral perfusion.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
Adult: 5-20 mCi (185-740 MBq) administered intravenously as a single dose for brain imaging; dose is based on patient weight and imaging protocol.
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
Terminal half-life is 6-8 hours; clinical context: allows for daily dosing in imaging studies.
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Renal: 50-65% unchanged; fecal: 35-50% as metabolites; total renal elimination accounts for ~70% of dose, with 30% undergoing biliary excretion.
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical